Diabetes
Conditions
Interventions
GROUP A:MMTT will be conducted at baseline. 1w after enrolment MMTT will be conducted togather with acarbose 100mg ,po, once. Then patients will be treated 50mg tid in first 2w and increase to 100mg t
GROUP B:Same procedure as group A except OGTT instead of MMTT.
CONTROL:Healthy subjects with NGT will not be randomly included into group C as control. OGTT will be conducted at enrolment and MMTT will be conducted 1 week apart
Sponsors
Guangdong General Hospital
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age 30-60yrs; 2. New diagnosed T2DM within 3 months; 3. FPG>7.0mmol/L and =18kg/m2; 4. Without any antihyperglycemic drug and medication known to alter carbohydrate metabolism treatment; 5. Provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Previously gastrointestinal surgery; 2. Gastrointestinal disorders and/or be on medications known to alter gastrointestinal motility; 3. Any condition where increased gas in the intestine may make it worse,such as Roemheld syndrome, large hernia, intestinal obstruction and intestinal ulcer; 4. Moderate to severe liver, kidney dysfunction ,ie ALT/AST > 2.5 times upper limit of the normal range or Ccr<25ml/min; 5. Previously allergic reaction to any of the ingredients of acarbose; 6. Any other condition or major systemic diseases that the investigator feels would interfere with trial participation or evaluation of results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| plasma fasting glucose and postprandial glucose(2h), and HbA1c, serum GLP-1, GIP, secreting pattern and AUCS;Blood fat (total cholesterol and triglycerides, high-density lipoprotein cholesterol (HDL-c), LDL-c; | — |
Secondary
| Measure | Time frame |
|---|---|
| serum GOT, ALT, ALP, cholinesterase, AST;urine HCG (if available);serum creatinine, BUN, URIC CO2CP; | — |
Countries
China
Contacts
Public ContactKuangjian, Yang Huazhang
Outcome results
None listed